How to minimise biologic viral contamination
contamination during biologic drug manufacturing.
During biological drug production, there is a risk of virus contamination across the entire procedure, from raw materials to processing.
The free white paper reviews the potential sources of viral contamination, the various virus concerns during manufacturing and cell bank characterisation of virus safety.
Because of the high contamination risk, virus testing is required during the making of biological products and the paper - produced by US contract testing and manufacturing provider Microtest - also claims to advise companies on ways to effectively partner with a contract testing laboratory.
"A proper testing program is essential to ensure the biological product achieves the fastest time to market," said the firm.
"By working with a qualified contract laboratory, the best testing strategy can be executed to assure product safety."
The white paper, titled: "Virus Testing for Biological Products: Partnering With a Contract Lab," can be found here
Microtest has been active in providing free advice in the form of white papers of late, releasing another one back in November aimed at pharma companies who are looking to choose a suitable contract manufacturer to aseptically produce injectable drug products, which it claims can be "a challenging task."
According to Microtest, "the ramifications of making a poor decision when selecting this highly specialised type of contractor can result in schedule delays, regulatory approval issues, and lost revenue."
